Discovery of novel ID2 antagonists from pharmacophore-based virtual screening as potential therapeutics for glioma. (1st November 2021)

• Record Type: Journal Article
• Authors: Zhong, Genshen; Wang, Yichun; Wang, Qi; Wu, Minna; Liu, Yichuang; Sun, Shitao; Li, Zhenli; Hao, Jinle; Dou, Peiyuan; Lin, Bin
• Is Part Of: Bioorganic & medicinal chemistry. Volume 49(2021)
• Publication Date: 2021-11-01
• Subjects: Glioma -- Inhibitor of differentiation -- Pharmacophore -- Virtual screening; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; Biochemistry -- Periodicals; Chemistry, Clinical -- Periodicals; Chemistry, Organic -- Periodicals; Chimie bio-organique -- Périodiques; Chimie pharmaceutique -- Périodiques; 615.19
• DOI: 10.1016/j.bmc.2021.116427
• Languages: English
• ISSNs: 0968-0896

Abstract

Graphical abstract: Highlights: Two pharmacophores were built from the first-in-class pan-ID antagonist AGX51. A pharmacophore-based virtual screening was carried out and 16 hit compounds were purchased for pharmacological evaluations on glioma inhibition. Compound AK-778-XXMU was identified to be a potent ID2 antagonist in the submicromolar range (KD : 129 nM). Abstract: Glioma, especially the most aggressive type glioblastoma multiforme, is a malignant cancer of the central nervous system with a poor prognosis. Traditional treatments are mainly surgery combined with radiotherapy and chemotherapy, which is still far from satisfactory. Therefore, it is of great clinical significance to find new therapeutic agents. Serving as an inhibitor of differentiation, protein ID2 (inhibitor of DNA binding 2) plays an important role in neurogenesis, neovascularization and malignant development of gliomas. It has been shown that ID2 affects the malignant progression of gliomas through different mechanisms. In this study, a pharmacophore-based virtual screening was carried out and 16 hit compounds were purchased for pharmacological evaluations on their ID2 inhibitory activities. Based on the cytotoxicity of these small-molecule compounds, two compounds were shown to effectively inhibit the viability of glioma cells in the micromolar range. Among them, AK-778-XXMU was chosen for further study due to its better solubility in water. A SPR (Surface Plasma Resonance) assay proved the high affinity between AK-778-XXMU and ID2 protein with the KD value as 129 nM. The plausible binding mode of ID2 was studied by molecular docking and it was found to match AGX51 very well in the same binding site. Subsequently, the cancer-suppressing potency of the compound was characterized both in vitro and in vivo . The data demonstrated that compound AK-778-XXMU is a potent ID2 antagonist which has the potential to be developed as a therapeutic agent against glioma.